These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 25118480

  • 1. Toxicity of concurrent chemoradiotherapy for locally advanced cervical cancer.
    Jakubowicz J, Blecharz P, Skotnicki P, Reinfuss M, Walasek T, Luczynska E.
    Eur J Gynaecol Oncol; 2014; 35(4):393-9. PubMed ID: 25118480
    [Abstract] [Full Text] [Related]

  • 2. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K, Cervical Cancer Vulva Cancer Committee of the Japanese Gynecologic Oncology Group.
    Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
    Schefter TE, Winter K, Kwon JS, Stuhr K, Balaraj K, Yaremko BP, Small W, Gaffney DK.
    Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):1179-84. PubMed ID: 22342094
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC, Wang L, Lin JC, Jan JS.
    J Formos Med Assoc; 2015 Mar 15; 114(3):231-7. PubMed ID: 25777974
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL, Jian JJ, Cheng SH, Hsieh CI, Tan TD, Chang HJ, Hung CF, Horng CF, Soong T, Tsou MH.
    Gynecol Oncol; 2005 Apr 15; 97(1):126-35. PubMed ID: 15790448
    [Abstract] [Full Text] [Related]

  • 13. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W, Hou X, Yan J, Shen J, Lian X, Sun S, Liu Z, Meng Q, Wang D, Zhao M, Qiu J, Hu K, Zhang F.
    BMC Cancer; 2017 Aug 01; 17(1):510. PubMed ID: 28764676
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
    Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K, Cervical Cancer (Vulva Cancer) Committee of Japanese Gynecologic Oncology Group (JGOG).
    Gynecol Oncol; 2012 Aug 01; 126(2):211-6. PubMed ID: 22555110
    [Abstract] [Full Text] [Related]

  • 15. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
    Zhang GY, Zhang R, Bai P, Li SM, Zhang YY, Chen YR, Huang MN, Wu LY.
    BMC Cancer; 2022 Dec 20; 22(1):1331. PubMed ID: 36539745
    [Abstract] [Full Text] [Related]

  • 16. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.
    Rose PG, Sill MW, McMeekin DS, Ahmed A, Salani R, Yamada SD, Wolfson AH, Fusco N, Fracasso PM.
    Gynecol Oncol; 2012 Apr 20; 125(1):158-62. PubMed ID: 22198338
    [Abstract] [Full Text] [Related]

  • 17. Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia.
    Kato S, Ohno T, Thephamongkhol K, Chansilpa Y, Yuxing Y, Devi CR, Bustam AZ, Calaguas MJ, de los Reyes RH, Cho CK, Dung TA, Supriana N, Mizuno H, Nakano T, Tsujii H.
    Int J Radiat Oncol Biol Phys; 2010 Jul 01; 77(3):751-7. PubMed ID: 19836154
    [Abstract] [Full Text] [Related]

  • 18. The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
    Mitsuhashi A, Usui H, Nishikimi K, Yamamoto N, Hanawa S, Tate S, Watanabe-Nemoto M, Uno T, Shozu M.
    Am J Clin Oncol; 2017 Apr 01; 40(2):118-121. PubMed ID: 25144265
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia.
    Wakatsuki M, Kato S, Ohno T, Banu PA, Hoang NC, Yadamsuren E, Supriana N, Cao J, Devi CRB, Calaguas MJ, Chansilpa Y, Cho CK, Adylkhanov T, Okonogi N, Nakano T, Tsujii H.
    Int J Radiat Oncol Biol Phys; 2019 Sep 01; 105(1):183-189. PubMed ID: 31125594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.